OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer.
BACKGROUND: Patients with advanced malignant adrenal tumors face poor prognoses with limited treatment options. CONCLUSIONS: These findings suggest that EO2401-based peptide immunotherapy combined with checkpoint inhibition can broaden and activate public, pre-existing T cell clusters, potentially enhancing tumor-specific immune responses.
BACKGROUND: Patients with advanced malignant adrenal tumors face poor prognoses with limited treatment options. CONCLUSIONS: These findings suggest that EO2401-based peptide immunotherapy combined with checkpoint inhibition can broaden and activate public, pre-existing T cell clusters, potentially enhancing tumor-specific immune responses.
What the study was
- Study design
- Not specified
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Communications medicine
Why it surfaced
Low-signal Novel therapeutics: immunotherapy, CAR-T, targeted therapy entry (Not specified design); retained for topic coverage completeness.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.